Development and validation of a High Performance Liquid Chromatographic method for determination of etoposide in biodegradable polymeric implants

Solano, Ana Gabriela Reis; Silva, Gisele Rodrigues da; Fialho, Sílvia Ligório; Júnior, Armando da Silva Cunha; Pianetti, Gérson Antônio

doi:10.1590/s0100-40422012000600032

Cited by 6 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The method described by Solano et al (23) was used to determine the amount of etoposide in the implants and that released in the in vitro study. The samples were analyzed using a Thermo Surveyor System (USA) that included a quaternary pump, an autosampler, a diode array detector, and ChromQuest 4.2 software.…”

Section: Hplc Methods For the Determination Of Etoposidementioning

confidence: 99%

Development and Evaluation of Sustained-Release Etoposide-Loaded Poly(ε-Caprolactone) Implants

et al. 2013

Self Cite

View full text Add to dashboard Cite

Poly(ε-caprolactone) implants containing etoposide, an important chemotherapeutic agent and topoisomerase II inhibitor, were fabricated by a melt method and characterized in terms of content uniformity, morphology, drug physical state, and sterility. In vitro and in vivo drug release from the implants was also evaluated. The cytotoxic activity of implants against HeLa cells was studied. The short-term tolerance of the implants was investigated after subcutaneous implantation in mice. The original chemical structure of etoposide was preserved after incorporation into the polymeric matrix, in which the drug was dispersed uniformly. Etoposide was present in crystalline form in the polymeric implant. In vitro release study showed prolonged and controlled release of etoposide, which showed cytotoxicity activity against HeLa cells. After implantation, good correlation between in vitro and in vivo drug release was found. The implants demonstrated good short-term tolerance in mice. These results tend to show that etoposide-loaded implants could be potentially applied as a local etoposide delivery system.

show abstract

Section: Hplc Methods For the Determination Of Etoposidementioning

confidence: 99%

Development and Evaluation of Sustained-Release Etoposide-Loaded Poly(ε-Caprolactone) Implants

et al. 2013

Self Cite

View full text Add to dashboard Cite

show abstract

“…It is a cytotoxic drug whose mechanism of action is the inhibition of the topoisomerase II enzyme (Stahelin and Vin 1991). Etoposide is widely used in chemotherapy for a variety of tumors, including lung, testicular, gastric tract, ovarian, retinoblastoma, and leukemia (Stahelin and Vin 1991;Solano et al 2012).…”

Section: Introductionmentioning

confidence: 99%

Toxicological study of the degradation products of antineoplastic agent etoposide in commercial formulation treated by heterogeneous photocatalysis using SrSnO3

Filho

Lobo

Grisólia

et al. 2018

Environ Sci Pollut Res

View full text Add to dashboard Cite

Etoposide is an antineoplastic agent used for treating lung cancer, testicular cancer, breast cancer, pediatric cancers, and lymphomas. It is a pollutant due to its mutagenic and carcinogenic potential. Disposal of waste from this drug is still insufficiently safe, and there is no appropriate waste treatment. Therefore, it is important to use advanced oxidative processes (AOPs) for the treatment and disposal of medicines like this. The use of strontium stannate (SrSnO) as a catalyst in heterogeneous photocatalysis reactions has emerged as an alternative for the removal of organic pollutants. In our study, SrSnO was synthesized by the combustion method and characterized by X-ray diffraction (XRD), Raman, UV-Vis, and scanning electron microscopy (SEM) techniques, obtaining a surface area of 3.28 m g with cubic and well-organized crystallinity and a band gap of 4.06 eV. The experimental conditions optimized for degradation of an etoposide solution (0.4 mg L) were pH 5 and catalyst concentration of 1 g L. The results showed that the degradation processes using SrSnO combined with HO (0.338 mol L) obtained total organic carbon removal from the etoposide solution, 97.98% (± 4.03 × 10), compared with TiO, which obtained a mineralization rate of 72.41% (± 6.95 × 10-3). After photodegradation, the degraded solution showed no toxicity to zebrafish embryos through embryotoxicity test (OECD, 236), and no genotoxicity using comet assay and micronucleus test.

show abstract

Laccase-Assisted Degradation of Anticancer Drug Etoposide: By-Products and Cytotoxicity

et al. 2023

View full text Add to dashboard Cite

Development and validation of a High Performance Liquid Chromatographic method for determination of etoposide in biodegradable polymeric implants

Cited by 6 publications

References 9 publications

Development and Evaluation of Sustained-Release Etoposide-Loaded Poly(ε-Caprolactone) Implants

Development and Evaluation of Sustained-Release Etoposide-Loaded Poly(ε-Caprolactone) Implants

Toxicological study of the degradation products of antineoplastic agent etoposide in commercial formulation treated by heterogeneous photocatalysis using SrSnO3

Laccase-Assisted Degradation of Anticancer Drug Etoposide: By-Products and Cytotoxicity

Contact Info

Product

Resources

About